Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Belite Bio Q1 2024 GAAP EPS $(0.27) Beats $(0.28) Estimate

Author: Benzinga Newsdesk | May 14, 2024 02:51am

Belite Bio (NASDAQ:BLTE) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.28) by 3.57 percent. This is a 18.18 percent increase over losses of $(0.33) per share from the same period last year.

As of March 31, 2024, the Company had $95.5 million in cash and U.S treasury bills.

Posted In: BLTE